Patients on supraphysiologic doses of steroids or use of such within the previous six weeks
No chronic (>= 1 month) use of oral steroids at the time of study enrollment; inhaled or topical steroids are acceptable
No chronic (duration > 30 days) daily use of oral steroids
Patients must have discontinued steroids >= 1 week prior to registration to Step 0 and remain off steroids thereafter, except as permitted (see below); patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step 1, 3, 5, 7)\r\n* NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone 10 mg daily or less, or bioequivalent dose of other corticosteroid):\r\n** Temporary steroid use for computed tomography (CT) imaging in setting of contrast allergy\r\n** Low dose steroid use for appetite\r\n** Chronic inhaled steroid use\r\n** Steroid injections for joint disease\r\n** Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease\r\n** Topical steroid\r\n** Steroids required to manage toxicity related to study treatment, as described in the subprotocols\r\n** Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy\r\n*** NOTE: Steroids must be completed alongside last dose of chemotherapy
Patients requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steroids are not prohibited.
Are not using steroids for at least 7 days prior to trial treatment
Participants requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency; topical, inhaled, nasal and ophthalmic steroids are allowed
>= 4 weeks from protocol tissue procurement since resolution of all immune related toxicities and off systemic steroids >= 4 weeks; prophylactic use of steroids in preparation for radiologic exams are acceptable
Significant prior infusion reaction to monoclonal antibodies that required treatment with systemic steroids
Concurrent use of high dose of systemic steroids. The use of inhaled, topical and ophthalmic steroids is allowed.
Is on chronic systemic steroids.
Inhaled, intranasal, intraarticular, and topical steroids are permitted.
Use of prednisone or equivalent systemic corticosteroid within 2 weeks of treatment; use of inhaled, intranasal, intra-articular, and topical steroids is allowed; oral or IV steroids to prevent or treat IV contrast reactions are allowed
Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids or steroids given for the purpose of adrenal replacement given at physiologic doses
Concomitant treatment with systemic corticosteroids greater than physiologic doses. Topical (other than at the proposed vaccination sites) or inhalational steroids are permitted
Ongoing need for pharmacological immunosuppression, including steroids
All cancer therapy, including radiation, topical steroid, and chemotherapy, must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study; the only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (> 60 days) without change may continue use of either systemic steroid (equivalent to =< 10 mg per day of prednisone) or topical steroids are eligible for this study if the frequency and dosage steroids has not changed for 60 days prior to the study; these participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be discontinued\r\n* Patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (i.e., steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agents
Is currently receiving oral steroid treatment (inhaled steroids are permitted)
Concurrent use of systemic steroids (within 10 days of enrollment) will be excluded, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease) must have completed at least 10 days prior to enrollment; steroid use to prevent intravenous (IV) contrast allergic reaction or anaphylaxis in patients who have known contrast allergies is allowed at any time prior to enrollment
Subjects on systemic intravenous or oral steroid therapy (or other immunosuppressive, such as azathioprine or cyclosporin A) are excluded; subjects must have had at least 6 weeks of discontinuation of any steroid therapy (except that used as premedication for chemotherapy or contrast-enhanced studies) prior to enrollment; physiologic (replacement) doses of steroids as well as nasal, topical or inhaled steroids are allowed
For cohort 4 only (glioblastoma), patients must either not be receiving steroids, or be on a stable dose of steroids for at least five days prior to registration
All cancer therapy, including radiation, topical steroid, and chemotherapy must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study; the only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (> 60 days) without change may continue use of either systemic steroids (equivalent to < 10 mg per day of prednisone) or topical steroids are eligible for this study if the frequency and dosage steroids has not changed for 60 days prior to the study; these participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be discontinued; patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (ie, steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agents
Patients may take steroids for disease control up to 24 hours prior to study enrollment; topical steroids are allowed for CTCL patients as described in inclusion criteria above
Subjects receiving topical steroids or other topical treatments for CTCL within 2 weeks.
Concomitant use of high dose systemic steroids and other drugs such as calcitonin preparations, active vitamin D3 preparations, estrogen preparations, selective estrogen receptor modulators, vitamin K2 preparations, parathyroid hormones, phosphorus absorbers; Note, inhaled, topical steroids and low tapering doses of steroid especially in patients treated recently for brain metastases will be included
There is no need for steroids and patients have not had steroids at least 2 weeks
Has a diagnosis of immunodeficiency and is not on continuous daily immunosuppressive therapy within 7 days prior to the first dose of trial treatment; (subjects may receive steroids before or after SRS to prevent or manage cerebral edema; inhalational steroids are permitted)
Patients receiving concomitant immunosuppressive agents or chronic corticosteroid use, except those on steroid to control brain metastases, those on topical or inhaled steroids, or steroids given via local injection
Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)
Ongoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporine, or with a history of chronic use of any such medication within the last 4 weeks before enrollment; patients are excluded if they have any concurrent medical condition that requires the use of systemic steroids (the use of inhaled or topical steroids is permitted)
Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, eye drops or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent IV contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed
Patients on systemic steroids (except if solely for adrenal replacement) within two weeks of collection
There is no need for steroids and patients have not had steroids at least 2 weeks
Patients requiring steroids or other immunosuppressive therapy; low-dose or topical steroids are allowable if being used as replacement therapy
Any form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment excluding steroids; attempts should be made to have patient on lowest possible dose of steroids; these medical entities can be exacerbated by PD-1 blockade
Currently receiving or has received systemic corticosteroids within 4 weeks prior to starting study drug for management of brain metastases, or who have not fully recovered from side effects of such treatment; steroids for endocrine replacement or receipt of short-course of steroids during the preceding 4 week period as supportive medication such as for drug allergy, anti-emetic, etc. is allowed)
Concurrent use of systemic steroids or steroid eye drops; this is to avoid immunosuppression which may lead to potential complications with vaccinia (priming vaccination); nasal, topical or inhaled steroid use is permitted
Patients are excluded if they have any concurrent medical condition requiring the use of systemic steroids (the use of inhaled or topical steroids is permitted).
No systemic glucocorticoids will be permitted within 48 hours prior to study registration\r\n* Note: Topical steroids, bronchodilators and local steroid injections are permitted if clinically required
Anticancer topical therapy, including therapeutic doses of steroids, within 2 weeks prior to initiating study treatment; Note: Topical steroids at doses intended for symptom management are permitted prior to study enrollment and may continue during study treatment
Systemic steroids should be stopped 2 weeks before the start of treatment; topical and inhaled steroids are allowed
Current systemic steroid therapy (inhaled or topical steroids are also not allowed)
Immunosuppressed state (e.g. HIV, use of chronic steroids)
Active immunosuppressive or cytotoxic therapy (excluding topical steroids) for any other condition.
Concurrent use of systemic steroids or chronic use of immunosuppressant medications; recent or current use of inhaled steroids is not exclusionary
Concurrent use of systemic steroids or immunosuppressant medications; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary
Patients must not receive concurrent systemic or topical steroids or other skin directed therapy while on study
Concurrent use of systemic steroids or immunosuppressant medications; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary
Patients receiving chronic steroids and or immunosuppression
Patients receiving systemic steroid therapy for a chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's Disease, etc.). Topical steroids are also excluded. Nasal and inhaled steroids are permitted.
Have a diagnosis of immunodeficiency, either primary or acquired, or treatment with systemic steroids or any other form of immunosuppressive therapy within 7 days prior to C1D1. Exception: inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease as well as a one-time dose of immunosuppressive agents used prophylactically for contrast allergies
No systemic oral steroids administered within 28 days prior to initiating treatment on protocol; topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes
Patients must be at least 28 days post systemic steroids prior to enrollment
Ongoing use of other immunosuppressive medications, including oral steroids and excluding topical steroids
Patient may be on steroids or anti-epileptics
Subjects taking systemic (parentally or orally) corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism, are not eligible. Topical steroids are acceptable as are intranasal steroids.
Patients who require pharmacologic doses of corticosteroids; replacement, topical, ophthalmologic and inhalational steroids are permitted.
Concurrent use of systemic steroids or immunosuppressant medications
Concurrent use of systemic steroids; recent or current use of inhaled steroids is not exclusionary
Evidence of immune dysfunction as listed below:\r\n* Human immunodeficiency virus (HIV) positivity\r\n* Active autoimmune diseases requiring treatment or a history of autoimmune disease that might be stimulated by vaccine treatment; however, patients with vitiligo may be enrolled\r\n* Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent intravenous [IV] contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed
Systemic corticosteroid use within past 14 days; use of inhaled, intranasal, and topical steroids is acceptable
Known immunosuppressed conditions or active immunosuppressive therapy such as organ transplantation (including bone marrow transplant), high dose steroids, or human immunodeficiency virus (HIV); although a documented negative HIV test is not mandatory for enrollment, patients felt to have a high clinical suspicion for HIV will need to test negative prior to enrollment; use of topicals or eye drops containing steroids is acceptable; inhaled steroids are excluded
Requires no steroids within 4 weeks and have not used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion; the exception being patients on chronic physiologic dose of steroid (Turnstile II)
Patients must either not be receiving steroids, or be on a stable dose of steroids for at least five days prior to registration
Short course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (=< 7 days) must have been discontinued at least 6 days prior to study treatment; stable ongoing corticosteroid use (>= 30 days) up to an equivalent dose of 20 mg of prednisone is permissible\r\n* CTCL: Topical steroids that have been used for > 3 weeks may be continued\r\n* All other histologies (not CTCL): Topical steroids use is permissible without restriction
Chronic treatment with systemic steroids or other immunosuppressive agents; Note: topical or inhaled steroids are allowed
Chronic treatment with systemic steroids or another immunosuppressive agent with the following exceptions:\r\n* Intermittent steroids may be used on an as-needed basis (e.g. treatment for chemotherapy-related nausea)\r\n* Patients on physiologic replacement doses of steroids due to adrenal insufficiency for any reason may remain on these medications
No systemic oral steroids administered within 28 days prior to initiating treatment on protocol; topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes
Systemic immunosuppressive medications such as steroids; the following steroid formulations are permitted: intranasal, intra-articular, and inhaled steroids
Subjects on chronic steroid therapy > 5 mg/day within 2 weeks of screening except for inhaled, nasal, or topical steroids
Active immunosuppressive therapy (excluding topical steroids) for any other condition.
No steroids for at least 2 weeks prior to enrollment, and patient must not be expected to require steroids during the study period
Patients on supraphysiologic doses of steroids or use of such =< 6weeks prior to registration
Concurrent oral corticosteroid use aside from adrenal replacement, or use of other immunosuppressive agents (ex: infliximab); topical or inhaled steroids will be allowed
Patient must not have received immune suppressants: corticosteroids (for other than allergic reactions and anaphylaxis), cyclosporine or tacrolimus within 7 days of enrollment\r\n* Note: the use of topical and/or inhalational steroids is allowed
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study
Known intolerance to steroids or H1/H2-antagonists.
Concurrent systemic immunosuppressive therapy or steroid therapy with more than 7 consecutive days of steroids within the last 4 weeks except in association with preparative regimen and NK cell infusion-inhaled corticosteroids is permitted
Concomitant treatment with corticosteroids greater than physiologic doses (used in the management of cancer or non-cancer-related illnesses); topical (if not including the proposed vaccination sites) or inhalational steroids are allowed
Patients requiring chronic systemic treatment with steroids
Chronic treatment with steroids or any other immunosuppressant drugs
Concurrent use of systemic corticosteroids (nasal corticosteroids, inhaled steroids, adrenal replacement steroids, and topical steroids are allowed)
Ongoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporine, or with a history of chronic use of any such medication within the last 4 weeks before enrolment; patients are excluded if they have any concurrent medical condition that requires the use of systemic steroids (the use of inhaled or topical steroids is permitted)
Concurrent use of systemic steroids, except for physiologic doses of systemic steroids for replacement or local (topical, nasal, or inhaled) steroid use; limited doses of systemic steroids to prevent intravenous (IV) contrast, allergic reaction, or anaphylaxis (in patients who have known contrast allergies) are allowed; although topical steroids are allowed, steroid eye-drops are contraindicated
Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, eye drops or inhaled) steroid use; limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent IV contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed
Concurrent radiation, with or without steroids, or steroids alone for emergency conditions secondary to lymphoma (i.e. cord compression, etc.) will be permitted
Patients must not require chronic treatment with systemic steroids (inhaled steroids are allowed) or other immunosuppressive agents
Steroids for physiological replacement are allowed.
Is on chronic systemic steroids.
Patients who have received corticosteroids within 7 days prior registration are not eligible, UNLESS the patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 1 month prior; NOTE: low dose steroid use for control of nausea and vomiting will be allowed; topical steroid use and inhaled steroids are also permitted
Patients are ineligible if they have any concurrent medical condition requiring the use of systemic steroids; (use of inhaled or topical steroids is acceptable)
Use of systemic steroid therapy within 28 days of study screening; patients on inhaled or topical steroids are eligible
Inhaled steroids are permitted
Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ? 1 day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT scans.
Receipt of corticosteroids within 7 days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 1 month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use is permitted; inhaled steroids are permitted
Concurrent use of systemic steroids, through 72 hours post the last RNA CART19 infusion; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary\r\n* Therapeutic doses of steroids must be stopped > 72 hours prior to CTL019 infusion; however, the following physiological replacement doses of steroids are allowed: < 6-12 mg/m^2/day hydrocortisone or equivalent
Current treatment with steroids
Long-term use of systemic corticosteroids; patients with replacement steroids and not immunosuppressive steroids may enroll in the study
Current use of steroids
Prior treatment with systemic steroids within 4 weeks prior to lymphodepletion (except for physiologic replacement doses for adrenal insufficiency, premedication for contrast allergies for scans, and for drug fever related to targeted therapy)
Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment; patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible; the only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions; the use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency
Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for the use of allergic rhinitis or pulmonary disease) within 2 weeks of registration
Systemic steroids should be stopped 2 weeks before the start of treatment; topical and inhaled steroids are allowed
Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any time during study participation or within 6 months prior to enrolment.
History of contact dermatitis to clobetasol propionate or similarly fluorinated steroids or other steroids with the propionate ester
Have used any systemic steroids within 14 days of study treatment
Receipt of corticosteroids within 7 days prior to the first dose of study treatment, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 1 month prior to first dose of study treatment; low dose steroid use for the control of nausea and vomiting will be allowed; topical steroid use is permitted; inhaled steroids are permitted
Immunosuppressive therapy (excluding topical steroids) for any other condition =< 4 weeks prior to registration
Subjects taking systemic (parentally or orally) corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism, are not eligible. Topical steroids are acceptable as are intranasal steroids.
Participants may have had any number of previous hormonal therapies (antiandrogens including enzalutamide, estrogens, finasteride, dutasteride, ketoconazole) provided these were discontinued >= 4 weeks before starting the trial; prior therapy with steroids is allowed though these must be discontinued >= 2 weeks before starting the trial; inhaled, topical, and intra-articular steroids are allowed
Patients must not be on steroids other than for physiologic replacement
Concurrent anticancer treatment or concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 30 days before the start of trial treatment. Short-term administration of steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) is allowed
Any prior systemic antimyeloma therapy except oral steroids (dexamethasone up to a total dose of 160 mg or equivalent within 14 days prior to the first dose of study treatment). Use of topical or inhaled steroids is acceptable
Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)
Concurrent use of systemic steroids; recent or current use of inhaled steroids is not exclusionary
Used any systemic steroids within 28 days of study treatment
Ongoing immunosuppression with systemic steroids or other immune modulator
Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy
Chronic treatment with systemic steroids or another immuno-suppressive agent
Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs 14 days before initiation of study treatment. Steroids with no or minimal systemic effect (topical, inhalation) are allowed. Note: Subjects receiving bisphosphonate or denosumab are eligible provided that treatment was initiated ?14 days before first dose of AGEN2034. Note: Use of inhaled or topical corticosteroid is permitted. Note: Steroid pre-medication for radiographic imaging for dye allergies is permitted.
Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for the use of allergic rhinitis or pulmonary disease) within 2 months prior to registration
No concomitant therapy with steroids (replacement doses of steroids are allowed)
No concurrent use of systemic steroids, except for local (topical, nasal, or inhaled) steroid use (replacement doses of steroids allowed)
Subject should not be receiving any agent for fatigue including steroids, megace or opioids. NOTE: Subjects who have a contrast-induced allergy are allowed to receive steroids for their scans.
steroids are currently not required and more than 14 days since last steroid treatment
Subject does not require steroids or does not require escalating doses of steroids for at least 2 weeks prior to the first dose of study drug.
Use of daily and/or chronic oral or ocular steroids. Individuals must be off daily steroids for at least 3 weeks prior to enrolling into the trial
No concurrent systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e. prednisone, dexamethasone), continuous use of topical steroid creams or ointments, or ophthalmologic steroids; if a subject is currently taking corticosteroids, treatment should be discontinued two weeks prior to starting protocol therapy; occasional use of steroid inhalers is allowed
Chronic treatment with steroids or other immunosuppressive agents for medical conditions other than cancer. Patients who require steroids for treatment of tumor-associated cerebral edema are eligible.
use of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of SG2000.
Received systemic steroids within 30 days of study enrollment
Any steroid treatment except for that required for replacement therapy in adrenal insufficiency, topical or injected testosterone for hypogonadism, or inhaled steroids for the treatment of asthma
Subjects who require pharmacologic doses of corticosteroids; replacement doses, topical, ophthalmologic, and inhalational steroids are permitted
Treatment with oral/systemic corticosteroids =< 14 days prior to registration, with the exception of topical or inhaled steroids or steroids given for the purpose of antiemetics during chemotherapy
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids or steroid inhalers
If a patient had been taking steroids, at least 2 weeks must have passed since the last dose; patients stable on physiologic replacement doses of steroids or other forms of hormone replacement therapy are eligible
Concurrent use of systemic steroids
Current treatment with steroids
Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)
Concurrent use of corticosteroids (exception: nasal corticosteroids, inhaled steroids, adrenal replacement steroids and steroid creams are allowed)
Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use; limited pharmacologic doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent intravenous [I.V.] contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed
Any concurrent medical condition requiring the use of systemic steroids is not permitted (the use of inhaled or topic steroids is permitted)
Inhaled, intranasal, intraarticular and topical steroids are permitted
Used any systemic steroids within 28 days of study treatment
Concurrent steroids are allowed if dexamethasone dose is =< 16mg daily; if feasible, steroids should be weaned off once sorafenib has been initiated
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids or steroid inhalers\r\n* If a patient had been taking steroids, at least 2 weeks must have passed since the last dose
Systemic steroids within 1 week before enrollment except steroids used as part of an antiemetic regimen or maintenance-dose steroids for non-cancerous disease.
Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids
Systemic steroid (except inhaled steroids) or other immunosuppressive therapy administered for more than 10 days within 4 weeks of enrollment
Use of corticosteroids, thalidomide, bortezomib, or cytotoxic chemotherapy within 2 weeks of the first dose of elotuzumab except for steroids with little or no systemic absorption (ie, topical or inhaled steroids).
Current treatment with steroids
Patients receiving chronic treatment with oral steroids or another immunosuppressive agent (excluding steroids as part of the chemotherapy pre-medication or emetic medication)
Patient has received systemic corticosteroids or sedative antihistamines (dimenhydrinate, diphenhydramine, etc.) within 72 hours of day 1 of the study except as premedication for chemotherapy (e.g., taxanes); subjects who are receiving inhaled steroids for respiratory conditions or topical steroids for skin disorders can be enrolled
Use of systemic steroids, or other pharmacological agents such as methylphenidate for cancer-related fatigue
Chronic oral or intravenous systemic steroid use (defined as being used on a regular basis or who have a problem that has required ongoing use of steroids in the last 180 days for greater than 7 days)
Patients who have not completed their initial steroids
No concurrent use of chronic systemic steroids (defined as currently on more than 1 week of treatment)
Patients must be scheduled for tapering doses of (or no longer treated with):\r\n* Cyclosporine;\r\n* Tacrolimus;\r\n* Sirolimus;\r\n* Steroids (patients may be on physiologic doses of steroids)
Patients on chronic steroid therapy or other immunosuppressive therapy except for topical or inhaled steroids known to have low systemic absorption
Use of oral or systemic steroids or other anti?immune therapy =< 90 days prior to pre?registration; Note: Use of inhaled/nasal steroids is not exclusionary
Patients must be at least 28 days post systemic steroids prior to enrollment
Chronic, current or recent (within the past 2 weeks) use of systemic steroid doses equivalent to prednisone > 5 mg daily for continued use > 14 days; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic glucocorticoids within 28 days of the first planned dose of PROSTVAC-V/F; use of inhaled steroids, nasal sprays, and all topical preparations (creams, solutions, gels, ointments, etc.) for up to 5% of the body surface area is allowed
Recent (within 4 weeks of screening) or concomitant long term treatment with systemic steroids, immunosuppressive/immunomodulating drugs (e.g. cyclosporine, corticosteroids)\r\n* Intranasal, inhaled and/or topical steroids are permissible
Chronic administration of immunosuppressive agents or other immune-modifying drugs or chemotherapeutic agents within six months prior to the first vaccine dose; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
Therapeutic doses of corticosteroids within 7 days of leukapheresis or 72 hours prior to JCAR017 administration. Physiologic replacement, topical, inhaled, and intranasal steroids are permitted.
Patients must not have been taking steroids or are on a stable dose of steroids for at least 14 days before enrollment
Patients with known immunodeficiency, known autoimmune disease, or concurrent use of immunomodulatory agents including systemic steroids within 7 days prior to registration, are ineligible
Clinical requirement for systemic corticosteroids for control of cerebral edema or for enzyme-inducing anticonvulsants; (inhaled steroids and systemic steroids for chronic obstructive pulmonary disease [COPD] are permitted)
Taking ibuprofen, naproxen, other non-steroid anti-inflammatory drugs (NSAIDs), steroids (except inhaled steroids) within 14 days of study registration
Patients on chronic therapy with any systemic immunosuppressant (not counting inhaled steroids or steroid creams) for any reason, including autoimmune disease
Subjects with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study. Inhaled steroids and intra-articular steroid injections are permitted in this study.
Systemic treatment with steroids or other immunosuppressive agents within 30 days prior to entry. Physiological replacement with hydrocortisone or equivalent is acceptable.